Ten tech-bio start-ups were selected to take part in Stevenage Bioscience Catalyst’s innovative Catalyser Programme on 23 May to help them refine their commercialisation strategy and fulfil their growth potential.
The 2023 cohort was pooled from a very competitive field of companies across the UK poised to move from prototype stage into developing their first commercially viable product. The selected companies are: Consone AI; Genenet Technology; Kuano; Neobe Therapeutics; PentaBind; Plurify; RS&RS Scientific; Stratosvir; Turing Biosystems and VasoDynamics.
Delivered in collaboration with Triple Chasm and Mindstream AI, the programme utilises the latest data and digital technologies to support early stage innovation and help tackle the challenges faced by fledging companies in translating ideas into viable products with commercial, social and environmental impact.
The programme uses Triple Chasm’s 12 meso-economic vectors and proprietary tools to help businesses to scale up by identifying areas for further development. Over the course of eight weeks and delivered in 15 sessions, the programme will cover positioning, funding, market, IP management, manufacturing, distribution and human capital management and will end with startups pitching in front of investors at the Demo Day on 14th July.
At the programme’s core are 11 panel discussions featuring a total of 35 panellists that are renowned experts in the therapeutics field. This includes Jackie Hunter from Benevolent AI, Uday Phadke, CEO of Triple Chasm, Eagle Genomics, Cambridge Innovation Capital, Start Codon, CGT Catapult, Department of Business and Trade, IQVIA, Redx Pharma, Multiply AI, Virtarka, Dr Sally Ann Forsyth OBE, CEO at SBC - and many more leading representatives.
By taking part, companies will also benefit from being part of Stevenage Bioscience Catalyst’s thriving ecosystem and wider community including GSK, Cell and Gene Therapy Catapult (CGTC) and over 40 other growing therapeutics companies.
Marco Delise, PhD, Entrepreneurship & Business Development Director, said: “I am delighted to welcome the 2023 cohort to the Catalyser Programme. We had a particularly strong field of applicants. This is testament both to the calibre of the programme itself and Stevenage Bioscience Catalyst’s enviable reputation for nurturing bio-tech start-ups in a supportive and highly connected community.”